

February 27, 2003

1320 '03 MAR 19 P2:29

Mr. Robert Moore Office of Nutritional Products, Labeling & Dietary Supplements, HFS 811 Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740

RE:

Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS:
Enzymatic Therapy, Inc.	Cholestoril®	Pantethine	The breakdown of fat into energy requires the transport of fatty acids across cellular membranes.* Pantethine (as a component of coenzyme A and acyl carrier protein) is essential in this process.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By:

Robert Doster

Title: Senior Vice President of Scientific Affairs

Date: 2/21/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely.

Cholestoril 3e

Michael P. Devereux

Chief Financial Officer

825 Challenger Drive

Green Bay, WI 54311-8328 Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

· Jeven 975 0162

LET 11494

83664